Global cancer tyrosine kinase inhibitors market & clinical pipeline outlo...KuicK Research
“Global Cancer Tyrosine Kinase Inhibitors Market & Clinical Pipeline Outlook 2020” Report Highlights:
Introduction to Cancer Tyrosine Kinase Inhibitors
Signaling Pathway of Receptor Tyrosine Kinase
Advantage of Tyrosine Kinase Inhibitors for Treatment of Cancer
Applications of Tyrosine Kinase Inhibitor in Cancer Therapy
Global Tyrosine Kinase Inhibitors Market Overview
Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Company, Indication & Phase
Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline: 411 Drugs
Majority of Cancer Tyrosine Kinase Inhibitors in Preclinical Phase: 164 Drugs
Marketed Cancer Tyrosine Kinase Inhibitors: 32 Drugs
Global gene therapy market & pipeline insightKuicK Research
“Global Gene Therapy Market & Pipeline Insight” Market Highlight:
Gene Therapy Market Overview
Significance of Gene Therapy in Cancer Therapeutics
Current Applications of Gene Therapy to Cancer Treatment
Gene Therapy Market Dynamics: Drivers, Challenges & Future Outlook
FDA & AMA Guidelines for Gene Therapy
Gene Therapy Pipeline by Phase, Indications, Country & Company
Gene Therapy Pipeline: 246 Drugs
Marketed Gene Therapy: 2 (Gendicine & Rexin-G)
Cancer Gene Therapy Pipeline: 69 Drugs
"Global HIV Vaccine Market Future Outlook" Report Highlights:
Introduction to HIV Vaccines
Issues Related to the Development of HIV Vaccines
Parameters for Successful Commercialization of HIV Vaccines
Global HIV Vaccines Market Opportunity Analysis
Global HIV Vaccine Clinical Pipeline by Company & Phase
Global HIV Vaccine Clinical Pipeline: 100 Vaccines
Majority Vaccine in Preclinical Phase: 42 Vaccines
Global cancer tyrosine kinase inhibitors market & clinical pipeline outlo...KuicK Research
“Global Cancer Tyrosine Kinase Inhibitors Market & Clinical Pipeline Outlook 2020” Report Highlights:
Introduction to Cancer Tyrosine Kinase Inhibitors
Signaling Pathway of Receptor Tyrosine Kinase
Advantage of Tyrosine Kinase Inhibitors for Treatment of Cancer
Applications of Tyrosine Kinase Inhibitor in Cancer Therapy
Global Tyrosine Kinase Inhibitors Market Overview
Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Company, Indication & Phase
Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline: 411 Drugs
Majority of Cancer Tyrosine Kinase Inhibitors in Preclinical Phase: 164 Drugs
Marketed Cancer Tyrosine Kinase Inhibitors: 32 Drugs
Global gene therapy market & pipeline insightKuicK Research
“Global Gene Therapy Market & Pipeline Insight” Market Highlight:
Gene Therapy Market Overview
Significance of Gene Therapy in Cancer Therapeutics
Current Applications of Gene Therapy to Cancer Treatment
Gene Therapy Market Dynamics: Drivers, Challenges & Future Outlook
FDA & AMA Guidelines for Gene Therapy
Gene Therapy Pipeline by Phase, Indications, Country & Company
Gene Therapy Pipeline: 246 Drugs
Marketed Gene Therapy: 2 (Gendicine & Rexin-G)
Cancer Gene Therapy Pipeline: 69 Drugs
"Global HIV Vaccine Market Future Outlook" Report Highlights:
Introduction to HIV Vaccines
Issues Related to the Development of HIV Vaccines
Parameters for Successful Commercialization of HIV Vaccines
Global HIV Vaccines Market Opportunity Analysis
Global HIV Vaccine Clinical Pipeline by Company & Phase
Global HIV Vaccine Clinical Pipeline: 100 Vaccines
Majority Vaccine in Preclinical Phase: 42 Vaccines
“Global Cancer Kinase Inhibitors Market & Pipeline Insight” Report Highlight:
Classification & Mechanism of Kinase Inhibitors
Cancer Kinase Inhibitors Therapy Market Overview
Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country
Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country
Patent Analysis & Orphan Designation of Kinase Inhibitors
Cancer Kinase Inhibitors In Clinical Pipeline: 649 Drugs
Marketed Cancer Kinase Inhibitors: 35 Drugs
Global cancer kinase inhibitors market & pipeline insightKuicK Research
“Global Cancer Kinase Inhibitors Market & Pipeline Insight” Report Highlight:
Classification & Mechanism of Kinase Inhibitors
Cancer Kinase Inhibitors Therapy Market Overview
Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country
Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country
Patent Analysis & Orphan Designation of Kinase Inhibitors
Cancer Kinase Inhibitors In Clinical Pipeline: 649 Drugs
Marketed Cancer Kinase Inhibitors: 35 Drugs
Tigecycline Market Viewed as Crucial in Treatment of Hospital-Acquired PneumoniaTripti Avanti
Tigecycline is endorsed at regular intervals of 12 hours with moderate intravenous infusions. Patients enduring with hindered liver capacity should be prescribed a lower measurement of tigecycline. R&D efforts aimed at reducing tigecycline cost are also underway.
Cancer targeted therapy market & clinical insight 2015KuicK Research
“Cancer Targeted Therapy Market & Clinical Insight” Report Highlight:
Introduction & Categorization of Cancer Targeted Therapies
Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies
Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase
Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline
Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies
Global Cancer Targeted Therapeutics Market Dynamics
Future Prospects of Cancer Targeted Therapies
Cancer immunotherapy market & clinical pipelineKuicK Research
“Cancer Immunotherapy Market & Clinical Pipeline Insight” Report Highlights:
Cancer Immunotherapy Market Overview
Cancer Immunotherapy Market Dynamics
Cancer Immunotherapy Pipeline: 1080 Drug in Clinical Pipeline
Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country
Cancer Vaccine Clinical Pipeline by Phase & Country
Oncolytic Viruses Clinical Pipeline by Phase & Country
Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country
Cancer Cell Therapy Clinical Trial Insight by Phase & Country
Currently there are 605 Cancer Monoclonal Antibodies, 289 Cancer Vaccines, 40
Oncolytic Viruses Drugs, 64 Cytokines Therapies & 82 Cell Therapies are in Clinical
Pipeline
“Global Cancer Kinase Inhibitors Market & Pipeline Insight” Report Highlight:
Classification & Mechanism of Kinase Inhibitors
Cancer Kinase Inhibitors Therapy Market Overview
Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country
Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country
Patent Analysis & Orphan Designation of Kinase Inhibitors
Cancer Kinase Inhibitors In Clinical Pipeline: 649 Drugs
Marketed Cancer Kinase Inhibitors: 35 Drugs
Global cancer kinase inhibitors market & pipeline insightKuicK Research
“Global Cancer Kinase Inhibitors Market & Pipeline Insight” Report Highlight:
Classification & Mechanism of Kinase Inhibitors
Cancer Kinase Inhibitors Therapy Market Overview
Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country
Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country
Patent Analysis & Orphan Designation of Kinase Inhibitors
Cancer Kinase Inhibitors In Clinical Pipeline: 649 Drugs
Marketed Cancer Kinase Inhibitors: 35 Drugs
Tigecycline Market Viewed as Crucial in Treatment of Hospital-Acquired PneumoniaTripti Avanti
Tigecycline is endorsed at regular intervals of 12 hours with moderate intravenous infusions. Patients enduring with hindered liver capacity should be prescribed a lower measurement of tigecycline. R&D efforts aimed at reducing tigecycline cost are also underway.
Cancer targeted therapy market & clinical insight 2015KuicK Research
“Cancer Targeted Therapy Market & Clinical Insight” Report Highlight:
Introduction & Categorization of Cancer Targeted Therapies
Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies
Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase
Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline
Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies
Global Cancer Targeted Therapeutics Market Dynamics
Future Prospects of Cancer Targeted Therapies
Cancer immunotherapy market & clinical pipelineKuicK Research
“Cancer Immunotherapy Market & Clinical Pipeline Insight” Report Highlights:
Cancer Immunotherapy Market Overview
Cancer Immunotherapy Market Dynamics
Cancer Immunotherapy Pipeline: 1080 Drug in Clinical Pipeline
Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country
Cancer Vaccine Clinical Pipeline by Phase & Country
Oncolytic Viruses Clinical Pipeline by Phase & Country
Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country
Cancer Cell Therapy Clinical Trial Insight by Phase & Country
Currently there are 605 Cancer Monoclonal Antibodies, 289 Cancer Vaccines, 40
Oncolytic Viruses Drugs, 64 Cytokines Therapies & 82 Cell Therapies are in Clinical
Pipeline
Cancer targeted therapy market & clinical insight 2015KuicK Research
“Cancer Targeted Therapy Market & Clinical Insight” Report Highlight:
Introduction & Categorization of Cancer Targeted Therapies
Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies
Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase
Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline
Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies
Global Cancer Targeted Therapeutics Market Dynamics
Future Prospects of Cancer Targeted Therapies
Global breast cancer monoclonal antibodies market outlook 2020KuicK Research
" Global Breast Cancer Monoclonal Antibodies Market Outlook 2020" Report Highlights:
Breast Cancer Monoclonal Antibodies Mechanism
Global Breast Cancer Monoclonal Antibody Market Analysis
Breast Cancer Monoclonal Antibodies Pipeline by Company & Phase
Breast Cancer Monoclonal Antibodies Pipeline: 62 mAb
Majority Breast Cancer Monoclonal Antibodies in Preclinical Phase: 17 mAb
Marketed Breast Cancer Monoclonal Antibodies: 6 mAb
Download Global breast cancer monoclonal antibodies market outlook 2020KuicK Research
\" Global Breast Cancer Monoclonal Antibodies Market Outlook 2020\" Report Highlights:
Breast Cancer Monoclonal Antibodies Mechanism
Global Breast Cancer Monoclonal Antibody Market Analysis
Breast Cancer Monoclonal Antibodies Pipeline by Company & Phase
Breast Cancer Monoclonal Antibodies Pipeline: 62 mAb
Majority Breast Cancer Monoclonal Antibodies in Preclinical Phase: 17 mAb
Marketed Breast Cancer Monoclonal Antibodies: 6 mAb
Global breast cancer monoclonal antibodies market outlook 2020 1KuicK Research
" Global Breast Cancer Monoclonal Antibodies Market Outlook 2020" Report Highlights:
Breast Cancer Monoclonal Antibodies Mechanism
Global Breast Cancer Monoclonal Antibody Market Analysis
Breast Cancer Monoclonal Antibodies Pipeline by Company & Phase
Breast Cancer Monoclonal Antibodies Pipeline: 62 mAb
Majority Breast Cancer Monoclonal Antibodies in Preclinical Phase: 17 mAb
Marketed Breast Cancer Monoclonal Antibodies: 6 mAb
In recent years, the pharmaceutical industry has witnessed increased political interest and attention due to the increased recognition of the economic importance and financial impact of healthcare as a component of national budgets. Biologic drugs (biologics) have attracted the attention of politicians since biologics have moved out of the niche pharmaceutical arena to contribute 17% of global pharmaceutical sales, representing revenues of more than $120bn in 2009. The market for biologics is growing at twice the rate of pharmaceutical drugs, placing significant cost pressures on government, employers, insurers, and patients. Government and insurers are using several strategies to contain costs but must ensure that the financial burden placed on patients does not restrict access to the health care system. Establishing a regulatory pathway for ‘follow-on’ biologics (biosimilars) was therefore felt to be necessary by many stake holders to encourage competition and reduce prices. Many pharmacutical companies both large and small - are expecting their bottom line growth to be driven by biosimilars and are channeling their R&D budgets to compete in what – according to many - is going to be one of the hottest areas in a radically changing global pharmaceutical market.
Download Global cancer immunotherapy market outlook 2020KuicK Research
\"Global Cancer Immunotherapy Market Outlook 2020\" Report Highlight:
Introduction & Classification of Cancer Immunotherapy
Global Cancer Immunotherapy Pipeline by Company, Indication & Phase
Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication
Global Cancer Immunotherapy Pipeline: 1834 Drugs
Marketed Cancer Immunotherapies: 113 Drugs
Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb
Cancer Vaccines Pipeline: 312 Vaccines
Marketed Cancer mAb: 36 mAb
Marketed Cancer Vaccines: 12 Vaccines
Global cancer immunotherapy market outlook 2020KuicK Research
"Global Cancer Immunotherapy Market Outlook 2020" Report Highlight:
Introduction & Classification of Cancer Immunotherapy
Global Cancer Immunotherapy Pipeline by Company, Indication & Phase
Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication
Global Cancer Immunotherapy Pipeline: 1834 Drugs
Marketed Cancer Immunotherapies: 113 Drugs
Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb
Cancer Vaccines Pipeline: 312 Vaccines
Marketed Cancer mAb: 36 mAb
Marketed Cancer Vaccines: 12 Vaccines
Cancer immunomodulators market & pipeline insight 2020KuicK Research
"Cancer Immunomodulators Market & Pipeline Insight 2020" Report Highlights:
Introduction & Need of Cancer Immunomodulators
Cancer Immunomodulators Mechanism
Cancer Immunomodulators Clinical Pipeline By Company, Indication & Phase
Cancer Immunomodulators Clinical Pipeline: 747 Cancer Immunomodulators Drugs
Majority Cancer Immunomodulators in Preclinical Phase: 300 Marketed Cancer Immunomodulators Clinical Insight
Marketed Cancer Immunomodulators: 47
Cancer Immunomodulators Drug Patent Analysis
Download Cancer immunomodulators market & pipeline insight 2020KuicK Research
\"Cancer Immunomodulators Market & Pipeline Insight 2020\" Report Highlights:
Introduction & Need of Cancer Immunomodulators
Cancer Immunomodulators Mechanism
Cancer Immunomodulators Clinical Pipeline By Company, Indication & Phase
Cancer Immunomodulators Clinical Pipeline: 747 Cancer Immunomodulators Drugs
Majority Cancer Immunomodulators in Preclinical Phase: 300 Marketed Cancer Immunomodulators Clinical Insight
Marketed Cancer Immunomodulators: 47
Cancer Immunomodulators Drug Patent Analysis
Global cancer biosimilars market opportunity outlookKuicK Research
"Global Cancer Biosimilars Market Opportunity Outlook" Report Highlight & Findings:
Introduction & Mechanism of Cancer Biosimilars
Global Cancer Biosimilars Market Dynamics
FDA & EMA Guidelines on Development & Marketing of Biosimilars
Cancer Biosimilars Clinical Pipeline by Company, Indication & Phase
Cancer Biosimilars Clinical Pipeline: 100 Biosimilars
Marketed Cancer Biosimilars Clinical Insight
Marketed Cancer Biosimilars: 15 Biosimilars
Global cancer biosimilars market opportunity outlookKuicK Research
"Global Cancer Biosimilars Market Opportunity Outlook" Report Highlight & Findings:
Introduction & Mechanism of Cancer Biosimilars
Global Cancer Biosimilars Market Dynamics
FDA & EMA Guidelines on Development & Marketing of Biosimilars
Cancer Biosimilars Clinical Pipeline by Company, Indication & Phase
Cancer Biosimilars Clinical Pipeline: 100 Biosimilars
Marketed Cancer Biosimilars Clinical Insight
Marketed Cancer Biosimilars: 15 Biosimilars
Similar to Download Tyrosine kinase inhibitors market & pipeline insight 2015 (20)
Global cancer cdk inhibitors market & clinical pipeline outlook 2022KuicK Research
“Global Cancer CDK Inhibitors Market and Clinical Pipeline Outlook 2022” report highlights:
* Selectivity and Working Mechanism of a Cancer CDKs Inhibitor
* Recent Advances in the CDKs Related Cancer Therapy
* Global Cancer CDK Inhibitors Clinical Trials Insight: 45 Drugs in Pipeline
* Market Opportunity Assessment: More Than US$ 20 Billion (2022)
* Price Analysis of Cancer CDKs Inhibitors:
* Sales Analysis of Available Drugs: More Than US$ 2 Billion (2017)
Cd antigen cancer therapy market outlook & clinical trials insight 2023KuicK Research
“CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023” report highlights:
• Market Opportunity Assessment: More than US$ 60 Billion by 2023
• Clinical & Patent Insight on 17 Commercialize CD Antigen Drugs
• Clinical & Licensing Insight on 184 CD Antigens in Clinical Pipeline
• Dosage & Price Analysis on Key Drugs
• Mechanism of CD Antigen Cancer Therapeutics
• Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 50 Drugs
• Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
Global orphan drug market designation status clinical pipeline trials insigh...KuicK Research
“Global Orphan Drug Market & Clinical Pipeline Insight 2023” Report Highlights:
• Clinical Insight on 800 Orphan Drugs
• Patent Insight, Orphan Designated Indication & Region/Country
• Marketed Orphan Drugs: More Than 300
• Maximum Orphan Designated Drugs in Phase-II: More Than 200
• Global Orphan Drug Designation Criteria
• FDA & EMA Guidelines
“US Shale Gas Industry Analysis” Report Highlight:
* US Shale Gas Industry Overview
* Shale Gas Exploration, Technical and Technology Aspects
* US Shale Gas Reserve Analysis: Technical & Recoverable Reserves
* Investments in Shale Gas Exploration & Production
* US Shale Gas Sector Dynamics
* Shale Boom to Drive LNG Export Projects
Download Us biosimilars market opportunity & clinical pipeline analysisKuicK Research
“US Biosimilars Market Opportunity & Clinical Pipeline Analysis” Report Highlight:
* US Biosimilars Market Introduction
* US Biosimilars Regulatory Scenario
* Unique Features of US Biosimilars Market
* Impact of Biosimilars in US Market
* Impact of Reimbursement Policies on US Biosimilars Market
* Zarxio: First Approved Biosimilar in US
* US Biosimilar Clinical Pipeline By Company, Indication & Phase
* US Biosimilar Clinical Pipeline: 104 Biosimilars
* Marketed Biosimilars: 1 Biosimilar*
Download Uae nuclear power sector opportunity analysisKuicK Research
“UAE Nuclear Power Sector Opportunity Analysis” Report Highlight:
* UAE Energy Policy beyond Oil & Gas
* UAE Nuclear Power Sector Overview
* UAE Nuclear Power Sector Dynamics
* Nuclear Power Sector Management & Regulatory Framework
* Nuclear Power Sector Regulations
* Details of Nuclear Power Plants in UAE
* UAE Nuclear Power Sector Future Outlook
Download Turkey wind power sector outlook 2017KuicK Research
“Turkey Wind Power Sector Outlook 2017” gives comprehensive insight on following aspect related to wind power sector development in Turkey:
* Wind Power Sector Overview
* Wind installed Capacity & Generation
* Operating Wind Farms by Province & Company
* Onshore & Offshore Wind Potential
* Emerging Trends
* Policy Framework
* Competitive Landscape
Download South korea wind power sector analysis 2013KuicK Research
“South Korea Wind Power Sector Analysis 2013” research report discusses following aspect related to emerging wind power sector in South Korea:
* Current Sector Trends
* Onshore & Offshore Wind Potential
* Wind Power Sector Indicators
* Operating Wind Farms
* Future Outlook & Sector Emerging Trends
* Regulatory & Policy Framework
* Competitive Landscape
Download Saudi arabia airport privatization opportunity outlook 2022KuicK Research
“Saudi Arabia Airport Privatization Opportunity Outlook 2022” report highlights:
Saudi Arabia Aviation Industry Overview
Privatization in Saudi Arabia
Investment and Expansion Opportunities for International Investors
Civil Aviation Laws and Policies Framework
Ongoing Privatization Projects
Privatization Build - Operateandndash;Transfer (BOT) Business Model
Download Non hodgkin lymphoma therapeutics market & pipeline insightKuicK Research
“Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight” Report Highlight:
Global Non Hodgkin Lymphoma Market Overview
Mechanism of Non Hodgkin Lymphoma Therapeutics
Global Non Hodgkin Lymphoma Pipeline by Type, Phase & Company
Global Non Hodgkin Lymphoma Pipeline: 204 Drugs
Majority of the Drugs are in Phase-I: 54 Drugs
Marketed Drugs for Non Hodgkin Lymphoma: 30 Drugs
Patent Analysis by Country, Year & Compositions
Download Nanoparticle drug delivery market & clinical pipeline insightKuicK Research
“Nanoparticle Drug Delivery Market & Clinical Pipeline Insight” Report Highlights:
Nanoparticle Drug Delivery Market Overview
Nanoparticle Drug Delivery Mechanism
Clinical Pipeline by Phase & Target Indications
Drug Profiles in Report: 190
Majority of Nanoparticle Drug in Preclinical Phase: 70
Marketed Nanoparticle Drugs: 12
Suspended & Discontinued Drug Profiles
Download Japan generics drug market outlook 2020KuicK Research
“Japan Generics Drug Market Outlook 2020” Report Highlights:
Introduction to Japanese Generic Drug Market
Attractiveness of Japanese Generic Market
Super Generics in Japan
Japan Healthcare System & Generic Drugs
Different Parameters for Generic & Branded Drugs
Comparison of Generic Drugs in US & Japan
Japan Generics Drug Market Analysis
Japan Generics Drug Market Future Prospects
Download India urban and industrial waste to energy marketKuicK Research
The Urban and Industrial waste based power projects have been witnessing upward trend in recent years driven by increasing investments from private sector and ongoing government initiatives to promote generation of power from urban and industrial waste. The overall installed capacity of grid connected waste power projects surpassed 70 MW by end of 2011 as compare to more than 90 MW of off grid waste base power projects.
Considering the huge potential to convert waste to energy in India, the Ministry of Environment and Forests had formulated the Municipal Solid Wastes Management and Handling Rules in 2000. Waste to Energy is understood as a renewable technology, and comes under the overall guidance and facilitation of the Ministry of Non Renewable Energy of India, which has announce finacila incentives and assistance programme in.
Download India nuclear power sector generation and investment opportunity out...KuicK Research
“India Nuclear Power Sector Generation and Investment Opportunity Outlook 2032” report highlights:
India Nuclear Power Sector Overview
India Nuclear Power Sector Indicators
India Existing and upcoming Nuclear Power Plants Overview
Indian Nuclear Power Regulatory and Policy Framework
India Nuclear Power Plants Infrastructure
India Nuclear Fuel Supply Scenario
Download Global cancer nanomedicine market outlook 2022KuicK Research
“Global Cancer Nanomedicine Market Outlook 2022” Report Highlights:
Overview and Mechanism of Action of Nanomedicine
Nanomedicine Engineering: Design and Strategy
Cancer Nanomedicine as Diagnostic and Therapeutics Tool
Global Cancer Nanomedicine Market Overview and Dynamics
Global Cancer Nanomedicine Clinical Pipeline by Company, Indication and Phase
Global Cancer Nanomedicine Clinical Pipeline: 124 Drug
Marketed Cancer Nanomedicine: 8 Drugs
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Download Tyrosine kinase inhibitors market & pipeline insight 2015
1. Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990 Page 1
Tyrosine kinase is a sub class of Protein Kinases family of enzyme responsible for
phosphorylation.It has been found that mutation or other anomaly in these enzymes causes
uncontrolled cell division leading to cancer. Because of their direct involvement in cell
division they are used in cancer treatment by using kinase inhibitors to prevent unregulated
cellular proliferation. Epidermal Growth Factor Receptor Family (EFGR) are present on the
cell surface and anomalies like mutations leads to the cancer formation and its members have
been found to have activity like receptor tyrosine kinases. EFGR Members of these families
have been found to be overexpressed in various malignancies like breast cancer, glioblastoma
and lung cancer. They are utilized for formulating targeted therapeutics for cancer
treatment. Her1/ Her2 are commonly found to be overexpressed in case of breast cancer and
many cancer therapeutics have been developed to treat metastatic condition.
Tyrosine kinase therapeutics segment is rapidly growing along with numerous products at
various phases of industry life cycle. Huge investments in research and development segment
could be attributed as main reason behind growth of this market segment. As a result, several
products are at different stages of clinical trials which will be introduced in market in coming
years. Some tyrosine kinase medical care products including mAbs are costly to produce but
large patient base and superior pharmacological benefits are some factors responsible for
continuous growth of this market segment. Development and discovery of innovative
technologies for commercialization is increasing because of large financial inputs. As a result,
more therapeutic options will be available to patients at cost effective rates. Their disease
coverage is increasing continuously due to which their market penetration is expected to
increase several folds in coming years.
Increasing disease incidences especially cancer has attracted several pharmaceutical
companies to invest in this segment. Imatinib (protein-tyrosine kinase inhibitor) for CML
treatment by Novartis was the first of this kind to enter in global market. Targeted
therapeutics offer superior pharmacological benefits due to which profit margin of tyrosine
kinase inhibitors are expected to increase in coming years. Small molecule based targeted
therapeutics will offer competition to monoclonal antibodies in terms of pharmacological
efficacy but pricing and commercialization strategies are also expected to play a major role.
Monoclonal antibodies are widely accepted across the globe due to higher safety and efficacy
profiles along with minimized side effects.
2. Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990 Page 2
Several mAbs biding to different tyrosine receptors have been formulated by pharmaceutical
companies generating significant revenues across the globe. For instance, Genentech’s
trastuzumab binds to HER2 for breast cancer treatment while Bevacizumab binds to VEGF to
treat NSCLC. Pharmaceutical companies are developing cancer drugs to target same receptor
kinase due to which severe competition would be found in certain categories. EFGR is widely
studied due to which majority of tyrosine kinase therapeutics belong to this category.
Moreover, it is involved in breast cancer which has well developed market so revenues
generated by this segment are expected to be significantly higher than other cancer
categories.
Clinical pipeline of tyrosine kinase therapeutics is quite strong due to which competitive
product are expected to enter continuously in global market. Owing to increasing disease
incidences, it has become imperative to take necessary steps to introduce innovative tyrosine
kinase therapeutics in global market. Technological advancements may allow the
investigators to develop products having high safety and efficacy levels along with minimized
side effects but it will take some time. Various products are at different stages of clinical
trials which will be introduced in global market in coming years. Higher cost effectiveness is
expected due to which sales is expected to increase and profit margins will increase. With all
these development, the future of tyrosine kinase therapeutics looks optimistic.
“Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015" Report Highlight:
• Global Tyrosine Kinase Therapeutics Market Overview
• Mechanism of Tyrosine Kinase Therapeutics
• Global Tyrosine Kinase Inhibitors Pipeline by Company, Indication & Phase
• Global Tyrosine Kinase Inhibitors Pipeline: 557 Drugs
• Majority Drugs in Preclinical Phase: 239 Drugs
• Marketed Tyrosine Kinase Inhibitors: 58 Drugs
• Marketed Tyrosine Kinase Inhibitors Clinical Analysis by Company & Indication
For Sample Report Contact: neeraj@kuickresearch.com
3. Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015
For Sample Contact: neeraj@kuickresearch.com , +91-11-47067990 Page 3
Table of Contents
1. Introduction to Tyrosine Kinases Inhibitors
2. Mechanism of Tyrosine Kinase Therapeutics
3. Global Tyrosine Kinase Therapeutics Market Overview
3.1 Current Market Scenario
3.2 Tyrosine Kinase Inhibitors Pipeline Overview
4. Global Tyrosine Kinase Therapeutics Market Dynamics
4.1 Favorable Market Parameters
4.2 Market Challenges
5. Global Tyrosine Kinase Therapeutics Market Future Prospects
6. Global Tyrosine Kinase Inhibitors Pipeline by Company, Indication & Phase
6.1 Unknown
6.2 Research
6.3 Preclinical
6.4 Clinical
6.5 Phase-I
6.6 Phase-I/II
6.7 Phase-II
6.8 Phase-II/III
6.9 Phase-III
6.10 Preregistration
6.11 Registered